CA3022006A1 - Composition comprenant des antigenes et un adjuvant pour les muqueuses et methode d'utilisation - Google Patents
Composition comprenant des antigenes et un adjuvant pour les muqueuses et methode d'utilisation Download PDFInfo
- Publication number
- CA3022006A1 CA3022006A1 CA3022006A CA3022006A CA3022006A1 CA 3022006 A1 CA3022006 A1 CA 3022006A1 CA 3022006 A CA3022006 A CA 3022006A CA 3022006 A CA3022006 A CA 3022006A CA 3022006 A1 CA3022006 A1 CA 3022006A1
- Authority
- CA
- Canada
- Prior art keywords
- composition
- suis
- antigens
- inactivated
- parasuis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 96
- 239000000427 antigen Substances 0.000 title claims abstract description 79
- 102000036639 antigens Human genes 0.000 title claims abstract description 79
- 108091007433 antigens Proteins 0.000 title claims abstract description 79
- 239000002671 adjuvant Substances 0.000 title claims abstract description 54
- 238000000034 method Methods 0.000 title claims description 31
- 241000606807 Glaesserella parasuis Species 0.000 claims abstract description 62
- 241000194021 Streptococcus suis Species 0.000 claims abstract description 54
- 241000606731 Actinobacillus suis Species 0.000 claims abstract description 51
- 201000010099 disease Diseases 0.000 claims abstract description 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 27
- 241001465754 Metazoa Species 0.000 claims abstract description 26
- 208000015181 infectious disease Diseases 0.000 claims abstract description 18
- 241000282898 Sus scrofa Species 0.000 claims description 27
- 230000003232 mucoadhesive effect Effects 0.000 claims description 19
- 230000001580 bacterial effect Effects 0.000 claims description 15
- 241001135989 Porcine reproductive and respiratory syndrome virus Species 0.000 claims description 12
- 229920002125 Sokalan® Polymers 0.000 claims description 11
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 10
- 241001135549 Porcine epidemic diarrhea virus Species 0.000 claims description 10
- 241000894006 Bacteria Species 0.000 claims description 9
- 230000028993 immune response Effects 0.000 claims description 9
- 241000588779 Bordetella bronchiseptica Species 0.000 claims description 8
- 241000588724 Escherichia coli Species 0.000 claims description 8
- 241000606856 Pasteurella multocida Species 0.000 claims description 8
- 241000725681 Swine influenza virus Species 0.000 claims description 8
- 229960005486 vaccine Drugs 0.000 claims description 8
- 241000186810 Erysipelothrix rhusiopathiae Species 0.000 claims description 7
- 241000202938 Mycoplasma hyorhinis Species 0.000 claims description 7
- 241001148549 Mycoplasma hyosynoviae Species 0.000 claims description 7
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 230000000415 inactivating effect Effects 0.000 claims description 7
- 239000002105 nanoparticle Substances 0.000 claims description 6
- 229960004279 formaldehyde Drugs 0.000 claims description 5
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 claims description 4
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical group O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 claims description 4
- 229920000642 polymer Polymers 0.000 claims description 4
- 229960000380 propiolactone Drugs 0.000 claims description 4
- 239000004094 surface-active agent Substances 0.000 claims description 4
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 claims description 4
- 229940033663 thimerosal Drugs 0.000 claims description 4
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 claims description 3
- 241000193163 Clostridioides difficile Species 0.000 claims description 3
- 241000193468 Clostridium perfringens Species 0.000 claims description 3
- 241000702665 Porcine rotavirus Species 0.000 claims description 3
- 239000004599 antimicrobial Substances 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 239000004584 polyacrylic acid Substances 0.000 claims description 3
- 239000003755 preservative agent Substances 0.000 claims description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 2
- 241000702619 Porcine parvovirus Species 0.000 claims description 2
- 229960001631 carbomer Drugs 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims description 2
- 230000002335 preservative effect Effects 0.000 claims description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 2
- 229930182490 saponin Natural products 0.000 claims description 2
- 150000007949 saponins Chemical class 0.000 claims description 2
- 239000000284 extract Substances 0.000 claims 1
- 239000007764 o/w emulsion Substances 0.000 claims 1
- 241000282887 Suidae Species 0.000 abstract description 45
- 238000002255 vaccination Methods 0.000 abstract description 16
- 238000011282 treatment Methods 0.000 abstract description 15
- 230000002163 immunogen Effects 0.000 abstract description 10
- 230000003115 biocidal effect Effects 0.000 abstract description 5
- 238000007918 intramuscular administration Methods 0.000 description 24
- 208000025814 Inflammatory myopathy with abundant macrophages Diseases 0.000 description 14
- 238000012545 processing Methods 0.000 description 12
- 230000008774 maternal effect Effects 0.000 description 11
- 238000002965 ELISA Methods 0.000 description 10
- 230000005875 antibody response Effects 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 230000004044 response Effects 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 208000005342 Porcine Reproductive and Respiratory Syndrome Diseases 0.000 description 7
- 230000001681 protective effect Effects 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 241000700605 Viruses Species 0.000 description 5
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 208000023504 respiratory system disease Diseases 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 235000015277 pork Nutrition 0.000 description 4
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical class CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 3
- 241000607142 Salmonella Species 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- PSLWZOIUBRXAQW-UHFFFAOYSA-M dimethyl(dioctadecyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC PSLWZOIUBRXAQW-UHFFFAOYSA-M 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000012770 revaccination Methods 0.000 description 3
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 201000008283 Atrophic Rhinitis Diseases 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical compound CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 description 2
- 241000204045 Mycoplasma hyopneumoniae Species 0.000 description 2
- 239000005662 Paraffin oil Substances 0.000 description 2
- 241001673669 Porcine circovirus 2 Species 0.000 description 2
- 206010039088 Rhinitis atrophic Diseases 0.000 description 2
- 206010000210 abortion Diseases 0.000 description 2
- 231100000176 abortion Toxicity 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 229960001212 bacterial vaccine Drugs 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 229960002518 gentamicin Drugs 0.000 description 2
- 244000144980 herd Species 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 210000002850 nasal mucosa Anatomy 0.000 description 2
- 229920002113 octoxynol Polymers 0.000 description 2
- 230000007479 persistent immune response Effects 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- -1 polyacrylic acids) Chemical class 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- ULQISTXYYBZJSJ-UHFFFAOYSA-N 12-hydroxyoctadecanoic acid Chemical compound CCCCCCC(O)CCCCCCCCCCC(O)=O ULQISTXYYBZJSJ-UHFFFAOYSA-N 0.000 description 1
- KIHBGTRZFAVZRV-UHFFFAOYSA-N 2-Hydroxyoctadecanoic acid Natural products CCCCCCCCCCCCCCCCC(O)C(O)=O KIHBGTRZFAVZRV-UHFFFAOYSA-N 0.000 description 1
- UMHYVXGZRGOICM-AUYXYSRISA-N 2-[(z)-octadec-9-enoyl]oxypropyl (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C)OC(=O)CCCCCCC\C=C/CCCCCCCC UMHYVXGZRGOICM-AUYXYSRISA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 241000606748 Actinobacillus pleuropneumoniae Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 206010069767 H1N1 influenza Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 206010028470 Mycoplasma infections Diseases 0.000 description 1
- 241000204003 Mycoplasmatales Species 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 208000009620 Orthomyxoviridae Infections Diseases 0.000 description 1
- 101710116435 Outer membrane protein Proteins 0.000 description 1
- 241000606860 Pasteurella Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 108010093965 Polymyxin B Proteins 0.000 description 1
- 206010036141 Polyserositis Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 150000001253 acrylic acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- REZZEXDLIUJMMS-UHFFFAOYSA-M dimethyldioctadecylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC REZZEXDLIUJMMS-UHFFFAOYSA-M 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 230000001983 lactogenic effect Effects 0.000 description 1
- 208000030175 lameness Diseases 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 229940049018 mycostatin Drugs 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- AFFLGGQVNFXPEV-UHFFFAOYSA-N n-decene Natural products CCCCCCCCC=C AFFLGGQVNFXPEV-UHFFFAOYSA-N 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- 229940060184 oil ingredients Drugs 0.000 description 1
- 150000002888 oleic acid derivatives Chemical class 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 229940051027 pasteurella multocida Drugs 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 208000008494 pericarditis Diseases 0.000 description 1
- 239000010773 plant oil Substances 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 229920000024 polymyxin B Polymers 0.000 description 1
- 229960005266 polymyxin b Drugs 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 229940010310 propylene glycol dioleate Drugs 0.000 description 1
- 238000000275 quality assurance Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- WBHHMMIMDMUBKC-XLNAKTSKSA-N ricinelaidic acid Chemical compound CCCCCC[C@@H](O)C\C=C\CCCCCCCC(O)=O WBHHMMIMDMUBKC-XLNAKTSKSA-N 0.000 description 1
- FEUQNCSVHBHROZ-UHFFFAOYSA-N ricinoleic acid Natural products CCCCCCC(O[Si](C)(C)C)CC=CCCCCCCCC(=O)OC FEUQNCSVHBHROZ-UHFFFAOYSA-N 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 201000010740 swine influenza Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La majorité de la mortalité observée chez les jeunes porcs se produit entre trois et cinq semaines après le sevrage pour des infections par S. suis et entre quatre et six semaines après le sevrage pour des infections par H. parasuis et des infections par Actinobacillus suis. La lutte contre les maladies cliniques associées à S. suis, A. suis et H. parasuis a été entreprise au moyen d'un traitement antibiotique, par une exposition contrôlée à des organismes vivants, et par une vaccination, à l'aide de bactérines commerciales ou autogènes inactivées administrées par voie parentérale. L'invention concerne une composition immunogène comprenant des antigènes et un adjuvant pour les muqueuses. La composition peut être administrée à des sujets, tels que des animaux, en particulier des porcelets pendant la période allant du pré-sevrage jusqu'à la phase de nourricerie, telle qu'à partir de la naissance ou de trois à cinq jours d'âge, pour les protéger de ces maladies.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2016/031902 WO2017196318A1 (fr) | 2016-05-11 | 2016-05-11 | Composition comprenant des antigènes et un adjuvant pour les muqueuses et méthode d'utilisation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3022006A1 true CA3022006A1 (fr) | 2017-11-16 |
Family
ID=60267492
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3022006A Pending CA3022006A1 (fr) | 2016-05-11 | 2016-05-11 | Composition comprenant des antigenes et un adjuvant pour les muqueuses et methode d'utilisation |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP3454893A4 (fr) |
| CA (1) | CA3022006A1 (fr) |
| WO (1) | WO2017196318A1 (fr) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112457397A (zh) * | 2020-11-26 | 2021-03-09 | 西北农林科技大学 | 一种prrsv n蛋白的纳米抗体及其制备方法和应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4944942A (en) * | 1987-08-27 | 1990-07-31 | Mobay Corporation | Intranasal vaccination of horses with inactivated microorganisms or antigenic material |
| TWI224107B (en) * | 1998-10-22 | 2004-11-21 | Pfizer Prod Inc | Novel proteins from actinobacillus pleuropneumoniae |
| MY129765A (en) * | 2000-12-19 | 2007-04-30 | Wyeth Corp | Improved mycoplasma hyopneumoniae bacterin vaccine |
| EP1742659B1 (fr) * | 2004-04-05 | 2013-03-13 | Pah Usa 15 Llc | Emulsions huile dans eau microfluidisees et compositions de vaccin |
| US7829274B2 (en) * | 2007-09-04 | 2010-11-09 | Boehringer Ingelheim Vetmedica, Inc. | Reduction of concomitant infections in pigs by the use of PCV2 antigen |
| WO2009134769A1 (fr) * | 2008-04-28 | 2009-11-05 | Novartis Ag | Nanoparticules destinées à être utilisées dans des compositions pharmaceutiques |
| WO2011059950A1 (fr) * | 2009-11-10 | 2011-05-19 | Boehringer Ingelheim Vetmedica, Inc. | Antigènes d'actinobacillus suis |
| BR122021013826B1 (pt) * | 2011-02-17 | 2022-11-22 | Boehringer Ingelheim Vetmedica Gmbh | Composição de proteína, ácido nucleico isolado e vetor de expressão recombinante |
| US20140179594A1 (en) * | 2011-04-21 | 2014-06-26 | The Rockefeller University | Streptococcus bacteriophage lysins for treatment of gram positive bacteria in companion animals and livestock |
| ES2662801T3 (es) * | 2012-06-27 | 2018-04-09 | Merial, Inc. | Vacunas atenuadas contra Streptoccocus suis y procedimientos de fabricación y uso de las mismas |
| CN104511015B (zh) * | 2013-09-30 | 2018-03-02 | 普莱柯生物工程股份有限公司 | 一种疫苗组合物及其制备方法与应用 |
| CN110075289A (zh) * | 2019-04-19 | 2019-08-02 | 河南省农业科学院畜牧兽医研究所 | 一种副猪嗜血杆菌、猪链球菌与胸膜肺炎放线杆菌三联灭活疫苗及其应用 |
-
2016
- 2016-05-11 WO PCT/US2016/031902 patent/WO2017196318A1/fr not_active Ceased
- 2016-05-11 EP EP16901833.0A patent/EP3454893A4/fr not_active Withdrawn
- 2016-05-11 CA CA3022006A patent/CA3022006A1/fr active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112457397A (zh) * | 2020-11-26 | 2021-03-09 | 西北农林科技大学 | 一种prrsv n蛋白的纳米抗体及其制备方法和应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017196318A1 (fr) | 2017-11-16 |
| EP3454893A4 (fr) | 2020-01-01 |
| EP3454893A1 (fr) | 2019-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10918711B2 (en) | Composition comprising antigens and a mucosal adjuvant and a method for using | |
| JP6294938B2 (ja) | 新規なアジュバント組成物 | |
| CN101175509B (zh) | 含有胞内劳森菌的免疫原性组合物 | |
| CN110087678B (zh) | 用于猪的组合疫苗 | |
| CN1152878A (zh) | 经改良修饰的brsv或疫苗 | |
| RU2420310C2 (ru) | ВАКЦИНА НА ОСНОВЕ Lawsonia И СПОСОБЫ ЕЕ ПРИМЕНЕНИЯ | |
| US10751403B2 (en) | Vaccine for protection against Streptococcus suis | |
| US20220323567A1 (en) | Combination vaccine for intradermal administration | |
| CA2931139C (fr) | Vaccin porcin contre le pprs et lawsonia intracellularis | |
| JP3178720B2 (ja) | パスツレラ・ムルトシダのトキソイドワクチン | |
| EP3883603A1 (fr) | Vaccin pour la protection contre streptococcus suis | |
| US9687544B2 (en) | Veterinary vaccine | |
| CA3022006A1 (fr) | Composition comprenant des antigenes et un adjuvant pour les muqueuses et methode d'utilisation | |
| CN112292149A (zh) | 针对猪圆环病毒的疫苗接种 | |
| JP2023113631A (ja) | クロストリジウム類毒素を含むワクチン | |
| RU2835620C1 (ru) | Комбинированная вакцина для внутрикожного введения | |
| Allam et al. | Use of rabbits as a laboratory model for evaluation of the combined inactivated respiratory virus vaccine (Pneumo-3) adjuvanted by Montanide oil (ISA 206) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20210510 |
|
| EEER | Examination request |
Effective date: 20210510 |
|
| EEER | Examination request |
Effective date: 20210510 |
|
| EEER | Examination request |
Effective date: 20210510 |
|
| EEER | Examination request |
Effective date: 20210510 |
|
| EEER | Examination request |
Effective date: 20210510 |
|
| EEER | Examination request |
Effective date: 20210510 |